2月27日周四盘中,百济神州(ONC)股价大涨6.04%,引发了市场的广泛关注。
百济神州公布2024年全年业绩显著向好,其核心产品百悦泽(泽布替尼胶囊)和百泽安(替雷利珠单抗)销售实现大幅增长。
据公告,2024年百悦泽全球销售额达到188.59亿元人民币,同比大增106.4%。其中美国、欧洲和中国市场均取得不俗表现。这款已获批多个适应症的BTK抑制剂在血液肿瘤治疗领域表现卓越,进一步巩固了公司的领先地位。
百泽安在2024年全年销售额同比增长17.4%至44.67亿元。此款PD-1单抗药物在中国市场份额领先,已获批14项适应症中的13项纳入国家医保目录。
随着核心产品销售持续放量,百济神州去年营业收入大增56.2%至272.14亿元。公司预计2025年营业收入将介于352亿至381亿元之间,同时经营利润和现金流也将转正。这一良好的经营预期推动了百济神州股价今日大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.